First recognized as a specific clinical entity by the discovery of an extra chromosome 18 in babies with a particular pattern of malformation by three independent groups (Edwards et al., Patau et al., Smith et al.).

Page Links: Introduction | Some Recent Findings | Mother's Age and Risk of Having a Baby With a Chromosomal Abnormality | Screening strategies for Down's syndrome | Checking your baby's health before birth | References | WWW Links | Glossary
Prenatal Diagnosis
Chitty LS, Kagan KO, Molina FS, Waters JJ, Nicolaides KH. Fetal nuchal translucency scan and early prenatal diagnosis of chromosomal abnormalities by rapid aneuploidy screening: observational study. BMJ. 2006 Feb 13
Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D'Alton ME. First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome. N Engl J Med. 2005 Nov 10;353(19):2001-2011. A large team of clinical researchers have compared the effectiveness of first and second trimester screening methods for this chromosome 21 trisomy disorder "First-trimester combined screening at 11 weeks of gestation is better than second-trimester quadruple screening but at 13 weeks has results similar to second-trimester quadruple screening. Both stepwise sequential screening and fully integrated screening have high rates of detection of Down's syndrome, with low false positive rates." First-trimester combined screening - nuchal translucency, pregnancy-associated plasma protein A [PAPP-A], free beta subunit of hCG (10 weeks 3 days through 13 weeks 6 days of gestation) Second-trimester quadruple screening - alpha-fetoprotein, total hCG, unconjugated estriol, and inhibin A at (15 through 18 weeks of gestation). (NEMJ Nov 10) NEMJ - Down's Syndrome Screening Article
This entry from Pedbase (click here to see original internet entry)
Pediatric Database (PEDBASE) Last Updated: 11/12/93
TRISOMY 18 SYNDROME
DEFINITION: A chromosomal disorder resulting in a syndrome characterized by specific (small) dysmorphic features and organ malformations.
EPIDEMIOLOGY:
HISTORY:
PATHOGENESIS:
1. Genetics
1. Trisomy 18
- 90% of cases
- due to meiotic nondisjunction
- less than 1% recurrence rate
2. Mosaicism
- 10% of cases
- due to postzygotic (postfertilization) mitotic nondisjunction
- leads to the partial clinical expression of Trisomy 18 with a longer survival
3. Translocations
- very rare
- give rise to partial trisomy 18 syndromes
- short arm:
- causes non-specific clinical features with mild or no mental deficiency
- long arm:
- entire:
- clinically indistinguishable from trisomy 18
- distal 1/3 -> :
- partial clinical picture of trisomy 18 with a longer survival and less profound mental retardation
CLINICAL FEATURES:
1. Dysmorphic Features
1. Facial
- microcephaly with prominent occiput
- narrow bifrontal diameter
- short palpabral fissures
- low-set malformed ears
- cleft lip +/- palate
- narrow palatal arch
- micrognathia
2. Skeletal
- neck
- webbed
- chest
- short sternum
- widely spaced nipples
- hips:
- small pelvis, congenital dislocation of the hips, limited hip abduction
- extremities:
- phocomelia
- rockerbottom feet or equinovarus
- short dorsiflexed big toes
- fixed flexion deformity of the fingers (overlapping of the 2nd and 5th fingers over the 3rd and 4th fingers)
- simple arch pattern of the fingers and toes
- hypoplasia of fingernails
- single crease of 5th finger or all fingers (absence of interphalangeal flexion creases)
- simian crease
2. Organ Malformations
1. Central Nervous System
- severe mental retardation
- hypotonia -> hypertonia
- neural tube defects
- poor suck and weak cry
- failure to thrive
- ocular anomalies
2. Respiratory
- apnea
3. Cardiovascular( >95%)
- major: VSD, ASD, PDA
- minor: transposition, ToF, coarctation, anomalous coronary artery, dextrocardia, aberrant subclavian artery, arteriosclerosis, PS, bicuspid aortic and/or pulmonic valves
4. Gastrointestinal
- inguinal, umbilical, and/or diaphragmatic hernia
- congenital defects:
- diastasis recti, heterotopic pancreas, malrotation, Meckel's, tracheoesophageal fistula
5. Genitourinary
- cryptorchidism
- congenital defects:
- double ureter, ectopic kidney, horseshoe kidney, hydronephrosis, polycystic kidney
INVESTIGATIONS:
1. Imaging Studies
- to rule out organ malformations:
- cardiovascular anomalies - Echo
- gastrointestinal anomalies - Barium Swallow, Endoscope
- genitourinary anomalies - Ultrasound
2. Karyotyping
MANAGEMENT:
1. Supportive
- very poor prognosis with:
- 30% dying by 1 month of age
- 50% dying by 2 months of age
- 90% dying by 12 months of age
- genetic counselling
- recurrence rate depends on genotype
| Age of Mother |
Risk of Down Syndrome |
Risk of Any Chromosomal Abnormality |
| 20 |
1 in 1667 |
1 in 526 |
| 21 |
1 in 1667 |
1 in 526 |
| 22 |
1 in 1429 |
1 in 500 |
| 23 |
1 in 1429 |
1 in 500 |
| |
1 in 1250 |
1 in 476 |
| 25 |
1 in 1250 |
1 in 476 |
| 26 |
1 in 1176 |
1 in 476 |
| 27 |
1 in 1111 |
1 in 455 |
| 28 |
1 in 1053 |
1 in 435 |
| 29 |
1 in 1000 |
1 in 417 |
| 30 |
1 in 952 |
1 in 384 |
| 31 |
1 in 909 |
1 in 384 |
| 32 |
1 in 769 |
1 in 323 |
| 33 |
1 in 625 |
1 in 286 |
| 34 |
1 in 500 |
1 in 238 |
| 35 |
1 in 385 |
1 in 192 |
| 36 |
1 in 294 |
1 in 156 |
| 37 |
1 in 227 |
1 in 127 |
| 38 |
1 in 175 |
1 in 102 |
| 39 |
1 in 137 |
1 in 83 |
| 40 |
1 in 106 |
1 in 66 |
| 41 |
1 in 82 |
1 in 53 |
| 42 |
1 in 64 |
1 in 42 |
| 43 |
1 in 50 |
1 in 33 |
| 44 |
1 in 38 |
1 in 26 |
| 45 |
1 in 30 |
1 in 21 |
| 46 |
1 in 23 |
1 in 16 |
| 47 |
1 in 18 |
1 in 13 |
| 48 |
1 in 14 |
1 in 10 |
| 49 |
1 in 11 |
1 in 8 |
Hook EB. Rates of chromosome abnormalities at different maternal ages. Obstetrics and Gynecology 58:282-285, 1981 (Data USA sourced)
Hook EB, Cross PK, Schreinemachers DM.Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA. 1983 Apr 15;249(15):2034-8.
Schreinemachers DM, Cross PK, Hook EB. Rates of trisomies 21, 18, 13 and other chromosome abnormalities in about 20 000 prenatal studies compared with estimated rates in live births. Hum Genet. 1982;61(4):318-24.
| Procedure |
Detection rate |
| First trimester screening (10 to 14 weeks): Maternal age Nuchal translucency measurement (by ultrasound) First trimester double test (PAPP-A, HCG) First trimester combined test (nuchal translucency, PAPP-A, HCG) |
32% 74% 63% 86% |
| Second trimester screening (15 to 19 weeks): Maternal age Second trimester double test (AFP, HCG) Triple test (AFP, HCG, uE3) Quadruple test (AFP, HCG, uE3, inhibin A) Integrated test (first trimester: nuchal translucency, PAPP-A; second trimester: quadruple test) |
32% 60% 68% 79% 95% |
| Prenatal diagnosis: Amniocentesis (15 weeks) Chorionic villus sampling (11-14 weeks) |
100% 100% |
Data from United Kingdom: Gilbert etal., British Medical Journal 2001; 323: 423)
AFP = fetoprotein, HCG = human chorionic gonadotrophin, PAPP-A = pregnancy associated plasma protein A, uE3 = unconjugated oestriol.
Termination: Surgical dilatation, evacuation (11 to 13 weeks), Medical with mifepristone (14 weeks)
Below is the NSW State Health Publication Checking your baby's health before birth. This Pamphlet is an example of the information made available to the general public on the diagnostic testing that can be carried out to check the genetic/physical status of the fetus.
Links: Ultrasound | Chorionic Villus Sampling (CVS)Amniocentesis
Every couple wants to have a healthy baby. For most couples, that will come true. However, there are some couples who have a greater chance than others of having a baby with a birth defect.
Special tests are available which are carried out during pregnancy to determine if the baby has a particular problem. These tests are generally referred to as prenatal diagnosis.
The ultrasound scan tells your doctor the age of the pregnancy and if you are carrying more than one baby. It can also be used to detect certain things wrong with the baby. This test is harmless to the mother and the baby.
The test is done by looking at cells taken from the placenta. No anaesthetic is required, and a test result is usually available in two to three weeks.
When the test is carried out by an obstetrician experienced in the technique, the risk of miscarriage related to the test is about 2 per cent (occurring in 1 in 50 pregnancies).
No anaesthetic is required, and a result is usually obtained in about three to four weeks. When the test is carried out by an obstetrician experienced in the technique, the risk of a miscarriage related to the test is about 1 per cent (occurring in 1 in 100 pregnancies).
Genetic counselling will provide current information about the disorder and support during this time. Ask your doctor for a referral or contact your local genetic counselling service for an appointment.
Further information can be obtained front the following centres. They specialise in prenatal diagnosis and related genetic counselling:
Camperdown
King George V Hospital
Fetal Medicine Unit
Camperdown NSW 2050
Tel: (02) 9515 8258
Royal Alexandra Hospital for Children- This Hospital has now moved to Westmead Campus as The Childrens Hospital.
Westmead
Westmead Centre
Fetal Medicine Unit
Westmead NSW 2145
Tel: (02) 9633 6800
Paddington - Royal Hospital for Women - This Hospital has now moved to Prince of Wales Campus
Randwick
Prince of Wales Children's Hospital
Department of Medical Genetics
Randwick NSW 2031
Tel: (02) 93994591
St Leonards
Royal North Shore Hospital
Fetal Medicine Unit
St Leonards NSW 2065
Tel: (02) 9438 7280
Penrith
Nepean Hospital
Fetal Medicine Unit
Penrith NSW 2750 Tel: (047) 924 2114
Newcastle
John Hunter Hospital
Prenatal Diagnosis Unit
Newcastle NSW 2310
Tel: (049) 921 4694
Genetic Education Program, Tel: (02) 438 7324 (Note: phone numbers in NSW are now 9438 7324)
Written in association with the NSW Genetic Education Program
PO. Box 317, St Leonards, NSW 2065. Tel: (02) 9438 7324.
State Health Publication Number (PA) 94-090
The Australian NHMRC(1988) recommends neonates be assessed for follow-up care under the following conditions.
(see the NHMRC WWW Page)
Reviews
Benn PA. Advances in prenatal screening for Down syndrome: II first trimester testing, integrated testing, and future directions. Clin Chim Acta. 2002 Oct;324(1-2):1-11.
Maymon R, Jauniaux E. Down's syndrome screening in pregnancies after assisted reproductive techniques: an update. Reprod Biomed Online. 2002 May-Jun;4(3):285-93.
Souter VL, Nyberg DA. Sonographic screening for fetal aneuploidy: first trimester. J Ultrasound Med. 2001 Jul;20(7):775-90.
Jackson M, Rose NC. Diagnosis and management of fetal nuchal translucency. Semin Roentgenol. 1998 Oct;33(4):333-8. Review.
Menendez M. Down syndrome, Alzheimer's disease and seizures. Brain Dev. 2005 Jun;27(4):246-52.
FitzPatrick DR. Transcriptional consequences of autosomal trisomy: primary gene dosage with complex downstream effects. Trends Genet. 2005 May;21(5):249-53.
Articles
Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D'Alton ME. First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome. N Engl J Med. 2005 Nov 10;353(19):2001-2011.
Hook EB, Cross PK, Schreinemachers DM.Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA. 1983 Apr 15;249(15):2034-8.
Schreinemachers DM, Cross PK, Hook EB. Rates of trisomies 21, 18, 13 and other chromosome abnormalities in about 20 000 prenatal studies compared with estimated rates in live births. Hum Genet. 1982;61(4):318-24.
Checking your baby's health before birth. State Health Publication Number (PA) 94-090
New triple screen test for Down syndrome: combined urine analytes and serum AFP. Bahado-Singh RO, et al. [See Related Articles] J Matern Fetal Med. 1998 May-Jun;7(3):111-4.
Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies R E Gilbert, C Augood, R Gupta, A E Ades, S Logan, M Sculpher, J H P van der Meulen, Euan M Wallace, and Sheila Mulvey BMJ 2001; 323: 423 (link to paper)
Noninvasive means of identifying fetuses with possible Down syndrome: a review. Kubas C. J Perinat Neonatal Nurs 1999 Sep;13(2):27-46 Women who are 35 years or older are offered invasive prenatal testing because of the increased risk of chromosomal abnormalities, especially Down syndrome. In an attempt to increase the number of Down syndrome fetuses being detected and decrease the number of invasive procedures being performed on pregnancies not affected with a chromosome abnormality, both biochemical and ultrasound screening methods are being studied and are summarized in this article.
The ultrasound markers reviewed include increased nuchal thickness, increased nuchal lucency, shortened femur, shortened humerus, pyelectasis, hypoplastic ears, echogenic intracardiac focus, hypoplasia of the fifth middle phalanx, and echogenic bowel.
Trisomy Organization http://www.trisomy.org/
Better Health Victoria trisomy disorders
Support Organization for Trisomy 18, 13, and Related Disorders
See also Virtual Hospital male Karyotype (Virtual Hospital inactive)
| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Numbers |
You should look at Development Notes for early normal development. In particular, look at the first week of development following fertilization.